Mireia-Atance-Pasarisas

Mireia Atance Pasarisas

Specialty:
Hematology and hemotherapy
Serving specialties:
  • Hematología y Hemoterapia
Hospitals where he/she works:
  • Hospital Universitario Fundación Jiménez Díaz
General Information
Experience

2013-Present: Associate Physician in the Molecular Cytogenetics Laboratory, Hematology and Hemotherapy Service, Hospital Universitario Fundación Jiménez Díaz

Degree

Bachelor's Degree in Chemistry (Universitat de Barcelona, 2011)

Bachelor's Degree in Biochemistry (Universitat de Barcelona, 2011)

Master's Degree in Reproductive Biology and Assisted Reproduction Techniques (Universitat Autónoma de Barcelona-I.Dexeus, 2012)

Thesis in Molecular Biosciences: "Genetic characterization of myelodysplastic syndromes: prognostic biomarkers and clonal evolution to acute myeloid leukemia" (Faculty of Medicine, Universidad Autónoma de Madrid, 2020)

Techniques

Conventional cytogenetics (karyotyping) of peripheral blood, bone marrow, lymph node, and biological fluid samples (pleural effusion, ascitic fluid, etc.)

Separation of CD138+ plasma cells for the study of multiple myeloma

Enrichment of granulocyte samples for the study of eosinophilia

Fluorescence in situ hybridization (FISH) with probes for the study of hematological malignancies

Massive sequencing: myeloid panel, lymphoid panel, and TP53 gene panel

Sanger sequencing

Research and teaching

Participation in various projects within the Hematology Service, highlighting "Immunophenotypic, molecular, and functional characterization of MSC-Like cells derived from patients with MDS."

Teaching assistant for the Hematology course in the Medicine degree program at the Autonomous University of Madrid

Internship tutor for the Hematology, Oncology, and Clinical Genetics course in the Medicine degree program at the Alfonso X University

Publications

Mireia Atance; Cristina Serrano; Carlos Soto; Juan Manuel Alonso-Domínguez; Carlos Blas; Raquel Mata; Tamara Castaño; Sara Perlado; Teresa Arquero; Jose Luis López-Lorenzo; M. Ángeles Pérez; Belen Rosado; Rafael Martos; Ana Rio-Machin; Pilar Llamas-Sillero; Rocio N. Salgado;Juana Serrano-López.2025. Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome.eJHaem

Yolanda Martínez-Díez; Aida Franganillo-Suárez; Rocío Salgado-Sánchez R; et al; Juan Manuel Alonso-Dominguez. 2022. Spontaneous Remission of Acute Myeloid Leukemia: A Case Report. Medicina. 58, pp.921.

Laura Pardo Gambarte; Aida Franganillo Suárez; Javier Cornago Navascués; et al; Laura Solan Blanco. 2022. ZBTB16-RARα-Positive Atypical Promyelocytic Leukemia: A Case Report.Medicina. Kaunas. 4-58, pp.520.

Cortés AA; Olmedillas S; Serrano-López J; et al; Alonso-Dominguez JM. 2020. Comparison of droplet digital PCR versus qPCR measurements on the international scale for the molecular monitoring of chronic myeloid leukemia patients. Molecular diagnosis and therapy.

Pérez-Sáenz MA; Rodriguez-Pinilla SM; Salgado RN; et al; Alonso Domínguez JM. 2020. Three monocytic neoplasms in a single patient. Leukemia &Lymphoma.

Book chapter. Miguel Alcoceba Sanchez; Mireia Atance Pasarisas; Cristina Bilbao Sieyro; et al; Mónica López Guerra. 2023. Leucemia linfática crónica. Recomendaciones sobre el estudio de secuenciación masiva en Neoplasias Hematológicas. Grupo de Biología Molecular en Hematología (GBMH)- Sociedad Española de Hematología y Hemoterapia.

Book chapter . Mireia Atance Pasarisas; Rosa Ayala Díaz; Concepción Fernández Rodríguez; et al; Maria Carmen Chillón Santos. 2023. síndromes mielodisplásicos. Recomendaciones sobre el estudio de secuenciación masiva en Neoplasias Hematológicas. Grupo de Biología Molecular en Hematología (GBMH)-Sociedad de Hematología y Hemoterapia.

Book chapter . Laura Palomo; Bárbara Tazón; Josep Nomdedéu; et al; Andrés Jerez. 2022. Diagnóstico y Pruebas Diagnósticas complementarias. Guía de Consenso de la hematopoyesis clonal de potencial indeterminado. Grupo español de síndromes mielodisplásicos. pp.35.

Communications and Presentations

Rocio Salgado; Mireia Atance; Sara Perlado; Teresa Arquero; Pilar LLamas; Ana Rio-Machin. Análisis genético y clínico de pacientes con diagnóstico de neoplasia mieloide y mutaciones germinales en DDX41. SEHH 2024. España.

Mireia Atance; Cristina Serrano; Carlos Soto; et al; Juana Serrano. Impact of niche cells in the progression of mds to secondary aml. European Hematology Association (EHA). 2024. España.

Mireia Atance; Sara Perlado; Javier Sanchez; et al; Rocío Salgado. Tp53 events in multiple myeloma: deletion, mutation or both?. XI Simposio del GECGH 2023. España.

Mireia Atance Pasarisas; Sara Perlado Marina; Carmen Carralero; et al; Rocío Salgado. Estudio De La Arquitectura Clonal De 29 Leucemias Mieloide Aguda Secundarias A Smd O Smd/Nmp Mediante Secuenciación Masiva. SEHH. 2021.

Atance M; Maieta P; Soto C; Pérez; Llamas P; Alvarez S; Cigudosa J; Salgado RN. Clinical and biological characterization of 53 mds patients using a targeted gene next generation sequencing panel. 14th International Symposium on Myelodysplastic Syndromes. 2017. España.

Awards and certifications

Secretary of the Oncohematological Genetics Committee of the Spanish Association of Human Genetics (AEGH) (2022-present)

Member of the Spanish Society of Hematology and Hemotherapy (SEHH), member of the Spanish Association of Human Genetics (AEGH), member of the Spanish Cooperative Group of Hematological Cytogenetics (GCECGH), member of the Molecular Biology of Hematology Group (GBMH), and member of the Spanish Group of Myelodysplastic Syndromes (GESMD).